Rationale and design of TRANSITION: a randomized trial of pre-discharge vs. post-discharge initiation of sacubitril/valsartan.

38 The trial was stopped prematurely because the primary outcome, a composite of death from cardiovascular causes or hospitalization for HF, showed highly significant superiority for sacubitril/valsartan compared with enalapril: 21.8% vs. 26.5% ( P < 0.001).

also in 132,142 other papers